Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.

Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks.

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today. The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. The United Kingdom (U.K.) Medicines and Healthcare p.

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive disease.

GLP-1 weight-loss drugs have pushed the biotech sector to new heights as demand steadily increases. But despite the drugs' popularity, there are other investment opportunities within the biotech sector.

These growth stocks are leading in their respective markets. Vertex Pharmaceuticals is the dominant force in the cystic fibrosis treatment industry, but it is in the midst of a multiyear period during which it's targeting multiple blockbuster launches.

The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.

Novo Nordisk is big but has plenty of room to grow. Vertex Pharmaceuticals' existing products and pipeline programs give it multiple growth catalysts.

Johnson & Johnson hasn't performed that well in the past decade. By contrast, Vertex Pharmaceuticals and Intuitive Surgical have been exceptional.

Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.